Recent Changes in the Epidemiology of Group A Streptococcus Infections: Observations and Implications
Microorganisms · 11.08.2025 · 13 (8) · 1871
DOI: 10.3390/microorganisms13081871 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 11.08.2025. Verfasst von Susanna Esposito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU-MUR M4C2.I.1.3PNRR, EU funding within the NextGenerationEU-MUR M4C 2.I.1.3PNRR Extended Partnership initiative on Emerging Infectious Diseases, INF-ACT Cascade Open Call 2023 (COC-1-2023-ISS-01).
Abstract (Originalsprache)
Streptococcus pyogenes (Group A Streptococcus, GAS) is a major human pathogen capable of causing infections ranging from mild pharyngitis and impetigo to severe invasive diseases such as bacteremia, necrotizing fasciitis, and streptococcal toxic shock syndrome (STSS). Historically, the incidence of GAS infections declined during the early antibiotic era but began rising again from the early 2000s, driven partly by the emergence of hyper-virulent strains such as emm1 and emm12. From 2005 onward, significant increases in GAS infections were reported globally, accompanied by rising antibiotic resistance, particularly to macrolides and tetracyclines. During the COVID-19 pandemic, widespread public health measures led to a sharp decline in GAS infections, including invasive cases, but this trend reversed dramatically in late 2022 and 2023, with surges exceeding pre-pandemic levels, notably in children. Recent data implicate factors such as “immunity debt,” viral co-infections, and the spread of virulent clones like M1UK. Looking forward, continued surveillance of GAS epidemiology, virulence factors, and resistance patterns is critical. Moreover, the emergence of GAS isolates with reduced susceptibility to beta-lactams underscores the need for vigilance despite the absence of fully resistant strains. The development of an effective vaccine remains an urgent priority to reduce GAS disease burden and prevent severe outcomes. Future research should focus on vaccine development, molecular mechanisms of virulence, and strategies to curb antimicrobial resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
- Università degli Studi di Milano, 20122 Milan, Italy.
ORCID-Profile: Susanna Esposito, Nicola Principi
Förderung
- NextGenerationEU-MUR M4C2.I.1.3PNRR
- EU funding within the NextGenerationEU-MUR M4C 2.I.1.3PNRR Extended Partnership initiative on Emerging Infectious Diseases
- INF-ACT Cascade Open Call 2023 (COC-1-2023-ISS-01)
Zitieren
APA
Esposito, S., Masetti, M., Calanca, C., Canducci, N., Rasmi, S., Fradusco, A., & Principi, N. (2025). Recent Changes in the Epidemiology of Group A Streptococcus Infections: Observations and Implications. Microorganisms, 13(8), 1871. https://doi.org/10.3390/microorganisms13081871
Vancouver
Esposito S, Masetti M, Calanca C, Canducci N, Rasmi S, Fradusco A, et al. Recent Changes in the Epidemiology of Group A Streptococcus Infections: Observations and Implications. Microorganisms. 2025;13(8):1871. doi:10.3390/microorganisms13081871
BibTeX
@article{Esposito2025,
author = {Esposito, Susanna and Masetti, Marco and Calanca, Carolina and Canducci, Nicolò and Rasmi, Sonia and Fradusco, Alessandra and Principi, Nicola},
title = {Recent Changes in the Epidemiology of Group A Streptococcus Infections: Observations and Implications},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {8},
pages = {1871},
doi = {10.3390/microorganisms13081871}
}
EUVIMED